Skip to main content
Universal Drugstore logo

Why pay full price for medications?

See Prices Now

Amjevita vs Humira: Understanding the Key Differences

In This Article

What Are Amjevita and Humira?

When facing an inflammatory condition like rheumatoid arthritis or Crohn’s disease, you may encounter two medication options that sound similar but have important differences: Amjevita and Humira. Understanding these medications can help you make informed decisions about your treatment.

Shop Medications

Humira (adalimumab) is a biologic medication that has been treating inflammatory conditions for many years. Amjevita (adalimumab-atto) is what doctors call a biosimilar to Humira.

Both medications work by blocking a protein called tumor necrosis factor alpha (TNF-α). This protein causes inflammation in your body. When these medications block TNF-α, they reduce the inflammation that causes pain and damage in conditions like arthritis.

The Main Difference: Biosimilar vs Original Biologic

The primary difference between Amjevita and Humira lies in their development and regulatory status. Humira is the original biologic medication, while Amjevita is a biosimilar version.

Why Pay Full Price?

Search our full medication catalogue and save up to 80% - no insurance needed.

See Prices Now

Think of a biosimilar like a generic medication, but for biologic drugs. Just as generic medications contain the same active ingredient as brand-name drugs, biosimilars are highly similar to their reference biologic.

Amjevita has no clinically meaningful differences in safety or effectiveness compared to Humira. This means doctors expect Amjevita to work just as well as Humira for treating your condition.

Approved Medical Conditions

Both Amjevita and Humira treat similar inflammatory conditions, but their approved uses are not identical.

Conditions both medications treat include:

  • Rheumatoid arthritis in adults
  • Psoriatic arthritis in adults
  • Ankylosing spondylitis in adults
  • Crohn’s disease in adults and children 6 years and older
  • Plaque psoriasis in adults
  • Hidradenitis suppurativa in adults
  • Uveitis in adults

However, Humira has additional pediatric approvals that Amjevita currently does not have. For example, Humira can treat juvenile idiopathic arthritis in children as young as 2 years old, while Amjevita’s pediatric approvals are more limited.

How These Medications Work in Your Body

Both Amjevita and Humira work through the same mechanism. They are monoclonal antibodies that target and block TNF-α.

When you have an inflammatory condition, your immune system produces too much TNF-α. This protein signals your body to create inflammation, which can damage your joints, intestines, or skin, depending on your condition.

By blocking TNF-α, both medications help reduce this harmful inflammation. This can lead to less pain, reduced swelling, and slower disease progression.

Administration and Dosing

Both Amjevita and Humira are given as subcutaneous injections. This means you inject the medication under your skin, similar to how people with diabetes inject insulin.

The dosing schedules for both medications are typically the same. Most adults receive injections every other week, though your doctor may adjust this based on your specific condition and response to treatment.

Both medications come in citrate-free formulations, which can reduce injection site pain compared to older versions.

Safety Profile and Side Effects

Since Amjevita is a biosimilar to Humira, both medications have very similar safety profiles and side effect risks.

Common Side Effects

The most frequently reported side effects for both medications include:

  • Injection site reactions such as redness, swelling, or itching
  • Upper respiratory infections like colds
  • Headache
  • Rash
  • Nausea

Serious but Rare Side Effects

Both medications carry similar warnings for more serious but less common risks:

  • Serious infections due to immune system suppression
  • Hepatitis B reactivation in people who previously had this infection
  • Severe allergic reactions
  • Lupus-like syndrome
  • Heart failure
  • Increased risk of cancer, including lymphoma, leukemia, and skin cancer
  • Nervous system problems, including conditions like Guillain-Barré syndrome and multiple sclerosis (MS)

These serious side effects are rare, but your doctor will monitor you carefully while you take either medication.

Effectiveness Comparison

Clinical studies show that Amjevita performs similarly to Humira in treating inflammatory conditions. The Arthritis Foundation notes that biosimilars like Amjevita are expected to have similar effectiveness and safety to their reference biologics.

Research comparing adalimumab biosimilars to the original Humira has found no significant differences in effectiveness for conditions like psoriasis and arthritis. This means you can expect similar results whether you use Amjevita or Humira.

Prescription and Substitution Rules

One important practical difference involves how pharmacies can dispense these medications. Amjevita is not approved as an interchangeable product with Humira.

This means that if your doctor prescribes Humira, your pharmacist cannot automatically substitute Amjevita without getting approval from your prescribing physician first. Your doctor must specifically prescribe Amjevita if that is the medication you will receive.

Cost Considerations

One of the main reasons biosimilars like Amjevita exist is to provide more affordable treatment options. While both medications can be expensive, Amjevita typically costs less than Humira.

The exact cost difference depends on your insurance coverage, pharmacy benefits, and other factors. Some patients find significant savings by switching to Amjevita, while others may find similar costs due to insurance negotiations or manufacturer programs.

If you are concerned about medication costs, consider exploring cash-pay options through Universal Drugstore, which may offer competitive pricing for both medications. Always discuss cost concerns with your healthcare provider and pharmacist to find the most affordable option for your situation.

Making the Right Choice for Your Treatment

When deciding between Amjevita and Humira, several factors should guide your decision:

Medical considerations: Your specific condition, age, and treatment history may influence which medication is most appropriate. For pediatric patients, Humira may be the only approved option for certain conditions.

Insurance coverage: Your insurance plan may prefer one medication over the other, affecting your out-of-pocket costs.

Doctor’s recommendation: Your healthcare provider knows your medical history and can advise which medication is best for your situation.

Previous treatment response: If you are already taking Humira successfully, your doctor may recommend continuing with it rather than switching.

What This Means for Patients

The availability of Amjevita provides patients with inflammatory conditions with more treatment options. As the first adalimumab biosimilar that was approved in the United States, Amjevita represents an important step toward making biologic treatments more accessible and affordable.

Both medications offer effective treatment for serious inflammatory conditions. The choice between them often comes down to practical considerations like insurance coverage, cost, and your doctor’s clinical judgment rather than significant differences in how well they work.

If you are currently taking Humira and considering a switch to Amjevita, or if you are starting treatment for the first time, discuss your options thoroughly with your healthcare provider. They can help you understand which medication is most appropriate for your specific situation and medical needs.

Remember that both Amjevita and Humira are powerful medications that require careful monitoring. Regular follow-up appointments with your doctor are essential, regardless of which medication you choose, to ensure safe and effective treatment of your inflammatory condition.

References

Related Conditions